Glipizide

Recent research reveals glipizide, a common diabetes drug, increases cardiovascular risks compared to DPP-4 inhibitors. This challenges assumptions about sulfonylureas, urging personalized treatment considering heart health alongside glycemic control in type 2 diabetes management.